[1] PARK J W, CHEN M, COLOMBO M, et al.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study[J]. Liver Int, 2015, 35(9): 2155-2166.
[2] ZHANG Z M, LAI E C, ZHANG C, et al.The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Int J Surg, 2015, 20: 8-16.
[3] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[4] CHUNG G E, LEE J H, KIM H Y, et al.Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology, 2011, 258(2): 627-634.
[5] BENSON A B, D'ANGELICA M I, ABBOTT D E, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019[J]. J Natl Compr Canc Netw, 2019, 17(4): 302-310.
[6] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J/CD]. 肝癌电子杂志, 2020, 7(1): 5-23.
[7] FINN R S, QIN S, IKEDA M, et al.Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[8] SHI J, LAI E C, LI N, et al.Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2010, 17(8): 2073-2080.
[9] FAN J, TANG Z Y, YU Y Q, et al.Improved survival with resection after transcatheter arterial hemoembolization (TACE) for unresectable hepatocellular carcinoma[J]. Dig Surg, 1998, 15(6): 674-678.
[10] ZHU X D, HUANG C, SHEN Y H, et al.Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations[J]. Liver Cancer, 2021, 10(4): 1-10.
[11] 曹俊宁, 张雯雯, 赵海涛, 等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J/CD]. 肝癌电子杂志, 2021, 8(2): 6-15.
[12] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6): 618-632 |
